Podcasts about Novo Nordisk

Hvordan slår man markedet gennem 20 år? Det ved dagens gæst i Millionærklubben en hel del om, for i mere end to årtier har han i snit leveret tæt på 19% årligt i afkast, altså langt mere end de ca. 9%, som verdensindekset har præsteret i samme periode. Heldigvis deler han gerne opskriften, så lyt med, når investor og indehaver af Jackson FamilieInvest, Thorleif Jackson, beskriver vejen til høj vækst i porteføljen. I studiet tager teknisk analytiker Lars Persson fra Aktierådet lytterne en tur ud på dagens marked, hvor bl.a. Novo Nordisk endnu engang er i fokus. Og sidst i udsendelsen kan du møde Søren Bentzen, der er kommet særdeles godt fra start i Millionærklubbens aktiespil. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

Novo Nordisk præsenterer stærke resultater for Wegovy til hjertepatienter. Novo-ansattes aktiegaver er tæt på at gå i 0. Onlinesupermarkedet Nemlig vil være profitable og billige. Hjemmearbejde på tilbagetog i finanssektoren viser undersøgelse. Grænser for topskat fastsat fra 2026. Xi, Putin og Modi mødtes i Shanghai. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

THE BEST BITS IN A SILLIER PACKAGE (from Monday's Mike Hosking Breakfast) Who Are the Inmates Exactly?/Don't You Listen to the News?/The Problem with Unions/The Problem with Weightloss Drugs/AnemophobiaSee omnystudio.com/listener for privacy information.

Evénements France Quantum : les vidéos de la quatrième édition du 10 juin à Station F, Paris, sont disponibles. https://www.youtube.com/playlist?list=PLHy9A3t7TeES-rvwyIHcY8_d8tYIfCp4L Bratislavahttps://www.oezratty.net/Files/Conferences/Olivier%20Ezratty%20ESSAI%20QT+AI%20Jul2025.pdf Innsbruck Osakahttps://www.qi2025.jp/ SQA Conference à Delft, sur les qubits supraconducteurs. https://www.sqa-conference.org/A venir en septembre et après : ·       Q2B Paris les 24 et 25 septembre à Paris https://q2b.qcware.com/conference/2025-paris·       DPG Gottingen la seconde semaine de septembre https://quantum25.dpg-tagungen.de/programm/industrietag·       Quantum Effects https://www.messe-stuttgart.de/quantum-effects/en/·       Quantum.Tech fin septembre à Rotterdam https://www.alphaevents.com/events-quantumtech·       Quantum Munich Software Forum fin octobre https://conference-questis.org/quest-is-2025/program/program-at-a-glance/·       GDR TEQ du CNRS à Grenoble du 12 au 14 novembre https://gdr-teq.cnrs.fr/·       QUEST-IS début décembrehttps://conference-questis.org/quest-is-2025/program/program-at-a-glance/ France Vidéo de vulgarisation de la physique et des technologies quantiques avec deux chercheurs du CEA, Nicolas Sangouard (IPhT) et Emmanuel Flurin (CEA-Iramis), dans un débat animé par Marie Treibert, une spécialiste de la vulgarisation scientifique.https://www.youtube.com/watch?v=6p1vQVZ__ZY Interview avec Valerian Giesz de Quandela pour la Société Générale.https://www.privatebanking.societegenerale.com/fr/actualites/ordinateur-quantique-big-bang-venir/Le livre d'Olivier en LateX International Une nouvelle suprématie quantique chez les Chinois avec des photons. Il s'agit de Jiuzhang 4.0, une nouvelle génération d'échantillonneur gaussien de bosons. Robust quantum computational advantage with programmable 3050-photon Gaussian boson sampling by Hua-Liang Liu, Jian-Wei Pan et al, arXiv, August 2025 (7 pages). Blueprint sur le FTQC FBQC dans la photonique avec des boites quantiquesPractical blueprint for low-depth photonic quantum computing with quantum dots by Ming Lai Chan, Aliki Anna Capatos, Peter Lodahl, Anders Søndberg Sørensen, and Stefano Paesani, arXiv, July 2025 (23 pages). QuEra continue de produire plein de papiers sur le FTQC Above 99.9% Fidelity Single-Qubit Gates, Two-Qubit Gates, and Readout in a Single Superconducting Quantum Device by Fabian Marxer, Antti Vepsäläinen, arXiv, August 2025 (35 pages). Levée de fonds de QuamCoreQuamCore Secures $26 Million Series A to Build 1-Million-Qubit Quantum Computer in a Single Cryostat by Matt Swayne, The Quantum Insider, August 2025. Marco Pistoia quitte JPMorganChase et rejoint IonQhttps://www.linkedin.com/posts/pistoia_research-quantumcomputing-quantumcommunications-activity-7353793320927567872-fXi7https://www.linkedin.com/posts/ionq-co_quantumcomputing-quantumnetworking-activity-7355560180954140672-12U3/ Début juillet, l'UE annonçait le lancement du Quantum Act. L'objectif est de faire de l'UE un leader mondial des technologies quantiques à l'horizon 2030.  https://digital-strategy.ec.europa.eu/en/library/quantum-europe-strategy Réaction du consortium QuiC avec un position paper qui insiste sur plusieurs points dont le besoin d'avoir aussi une stratégie dans le logiciel, et sur la sustainability :QuIC's Recommendations for the EU Quantum Strategy by Andy Penfold, QuIC, August 2025 (28 pages). A peu près au même moment, la fondation Novo Nordisk qui est le premier pourvoyeur de fonds des investissements quantiques au Danemark annonçait l'acquisition d'un ordinateur quantique d'Atom Computing, en partenariat avec Microsoft, qui dispose d'un petit laboratoire de recherche à Lyngby dans la banlieue nord de Copenhague. https://novonordiskfonden.dk/en/news/eifo-and-the-novo-nordisk-foundation-acquire-the-worlds-most-powerful-quantum-computer/ Bullshit Le CEO d'IonQ roi de la survente en ce moment chez les industry vendors.https://www.linkedin.com/posts/keith-king-03a172128_ionq-ceo-aims-to-build-a-trillion-dollar-activity-7363224769653039104-4_cQ Encrypted Qubits can be Cloned by Koji Yamaguchi, and Achim Kempf, arXiv, January 2025 (13 pages). “A Manifesto for Ontological Quantum Computing (Year 3000)” by Gonzalo Florez Giraldo. Avec de la conscience Quantique au programme. htt...

Oggi a Start parliamo dell'impatto sulla crescita della Danimarca delle difficoltà dell'azienda farmaceutica Novo Nordisk, poi di cosa vuol dire guerra ibrida nei paesi di Baltico e infine di una storia di innovazione e rispetto dell'ambiente che arriva da Trentino Alto Adige, Val di Non Learn more about your ad choices. Visit megaphone.fm/adchoices

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über KI-Optimismus bei Dell, eine neue Toniebox-Euphorie in Kinderzimmern und einen Analysten-Push für Siemens. Außerdem geht es um Ulta Beauty, Marvell, Gap, Amazon, Microsoft, Meta, Spotify, IBM, Alphabet, Bristol Myers Squibb, Argenx, Legend Biotech, Summit Therapeutics, Denali Therapeutics, Intellia, Regeneron, Immunocore, Viking Therapeutics, Novo Nordisk und Eli Lilly. Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Pardon? Microsoft, dat 49 procent van de aandelen van OpenAI in handen heeft, is zelf ineens aan het uitvinden geslagen. Het wil een eigen variant van ChatGPT hebben, om zo minder afhankelijk te zijn. Op zijn zachts gezegd een opvallend besluit, aangezien ze al 13 miljard dollar hebben uitgegeven aan de ontwikkeling van ChatGPT. Deze aflevering hebben we het over deze apart stap. Of is het juist een slimme tactiek van Microsoft om zelf te investeren in kunstmatige intelligentie?Bitcoin-bedrijf AMBTS komt ook voorbij. Het wil dolgraag naar de Amsterdamse beurs en lijkt een belangrijke horde daarvoor genomen te hebben. Vraag is alleen of beleggers er op zitten te wachten. NovoNordisk én Nike komen voorbij. Beide hebben het lastig, maar het Deense bedrijf maakt het wel heel bont. De groei van NovoNordisk holt zo terug dat het de hele groeiverwachting van de Deense economie naar beneden trekt. Verder hebben we het over de Fed. Minister Eelco Heinen maakt zich inmiddels zorgen over het 'inbeuken' van Trump op de centrale bank. En we gaan je voorbereiden op een periode zonder kwartaalcijfers. Nu het cijferseizoen zo goed als voorbij is, waar moet je nu op letten?See omnystudio.com/listener for privacy information.

SVM-regeringen præsenterer fredag sit bud på en finanslov med bl.a. sænket elafgift og penge til børnehaver. Økonomisk Redegørelse spår et stort fald i inflationen i 2026. Novo Nordisk har meddelt nyansatte, at de ikke skal starte alligevel. Investorer spekulerer i afnotering af Mærsk. Det fyrede Fed-medlem Lisa Cook sagsøger præsident Trump. S&P 500 i ny stor milepæl. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)  

Helmut Jonen aka Waikiki5800 ist zurück bei echtgeld.tv! Was bewegt einen Investor mit über 40 Jahren Börsenerfahrung dazu, ausgerechnet jetzt bei CK Hutchison, Berkshire Hathaway, Diageo und Nestlé aufzustocken? In seinem Comeback bei echtgeld.tv beleuchtet Helmut Jonen gemeinsam mit Tobias Kramer nicht nur Bewertungs-Chancen, sondern auch politische Risiken – vom US-Wahljahr über China bis zur deutschen Rentenkrise. Und er spricht über Value-Chancen im Depot und wie man in unruhigen Zeiten nachjustiert.

Join panelists Robert Kushner, MD, Jamy Ard, MD, and Jaime Almandoz, MD, to learn about BMI as a measure of excess adiposity, exploring both its strengths and limitations. Speakers:  -          Bob Kushner, MD  -          Jamy Ard, MD, FTOS -          Jaime Almandoz, MD, MBA, MRCPI, FTOS   This podcast is sponsored by Novo Nordisk and is intended for clinicians. Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners. © 2025 Novo Nordisk All rights reserved. US24OB00077 June 2025

Vindmøllegiganten Ørsteds aktie styrtdykkede mandag, og krisen er måske endnu mere alvorlig end som så. Ørsted er muligvis gidsel i en politisk strid mellem Danmark og USA, skriver Financial Times. Er hele havvindmølleeventyret lagt i koma? Kommer Trumps politiske had også til at ramme andre danske virksomheder som f.eks. Novo Nordisk? Vi diskuterer også Novo-topchefens Mike Doustdar sparekniv, der skaber vrede blandt de ansatte. Til sidst kigger vi på Trumps kvælertag på den uafhængige amerikanske centralbank, hvor han nu har fyret et medlem af den magtfulde bankledelse. I studiet: Magnus Barsøe og Frank Hvid. See omnystudio.com/listener for privacy information.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über den Swiftie-Push für Ralph Lauren, gute Nachrichten von Eli Lillys Abnehmpille und das bange Warten auf die Nvidia-Zahlen. Außerdem geht es um Novo Nordisk, AT&T, EchoStar, MongoDB, Okta, BASF, Commerzbank, BNP Paribas, Socitété Générale, Crédit Agricole, Axa, Procter&Gamble, SPDR MSCI Europe Consumer Staples ETF (WKN: A1191N), Nestlé, Unilever, L'Oreal, Anheuser Busch InBev, Amundi STOXX Europe 600 Consumer Staples ETF (WKN: LYX02J) und iShares MSCI EU Consumer Staples ETF (WKN: A2QBZ2). Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

To kapitalfonde Nordic Capital og Permira har nu aflagt et officielt opkøbstilbud på Bavarian Nordic. Uro i FED. Det er ikke kun i USA, at Novo Nordisk kæmper mod kopimedicin. Trump tvinger USA's giganter ind i statska­pi­ta­lisme. Flybranche og minister er dybt uenige om ny “grøn” rute.   Vært: Trine Duvander (trine.duvander@borsen.dk)

In this episode of The Daily Mastermind, host George Wright III welcomes an inspiring guest, the founder and CEO of Florida's Cotton Clouds, Onahira Rivas. She talks about her entrepreneurial journey from starting a business as a child to scaling multiple multimillion-dollar ventures. They share insightful lessons on leveraging corporate experience, implementing systems and SOPs, and the importance of sales and marketing as a foundation. The episode introduces the Bold Business Framework designed to help six and seven-figure business owners transform their businesses into legacy enterprises through sales and marketing, operational systems, investor readiness, and growth strategies. Real-world examples, including a car dealership's success story, illustrate the practical application of the framework. 02:05 Corporate Experience and Transition to Entrepreneurship04:07 Building and Scaling a Business06:22 Creating a Legacy and Manufacturing in America10:55 The Bold Business Framework17:57 Case Study: Transforming a Car Dealership23:27 Mindset Shifts for EntrepreneursYou have GREATNESS inside you. I BELIEVE in You. Let's Make Today the Day You Unleash Your Potential!George Wright IIICEO, The Daily Mastermind | Evolution X_________________________________________________________P.S. Whenever you're ready, here are ways I can help you…Get to know me:1. Subscribe to The Daily Mastermind Podcast- daily inspiration, motivation, education2. Follow me on social media Facebook | Instagram | Linkedin | TikTok | Youtube3. Get the Prosperity Pillars Poster I Developed over 20 years from my Mentors.Work with me:My mission is to help you Master Your Mind, Money, & Business, and I firmly believe:It's Never Too Late to Create the Life You Were Meant to Live…a LIFESTYLE of Health, Wealth, and Happiness. Here are ways I've been able to help thousands of people over the past 20 years…About the Guest: Onahira RivasOnahira Rivas is the founder and CEO of Florida's Cotton Clouds, the first woman-led cotton manufacturing facility in the U.S. With over two decades of global leadership experience at companies like Novo Nordisk and Bristol Myers Squibb, she has launched and scaled multimillion dollar brands across pharma, retail, and consumer goods. Onahira has introduced hundreds of products to major retailers and now focuses on purpose-driven business. Her work is rooted in values like resilience, transparency, and faith. She's a member of the Forbes Business Council, a winner of The Blox TV competition, and a passionate advocate for U.S.-based manufacturing and female leadership in business.Guest ResourcesValiant CEO Article: https://valiantceo.com/onahira-rivas-of-floridas-cotton-clouds-resilient-leadership-amidst-business-challenges/Website: https://onahirarivas.com/Florida Cotton Clouds Website: https://floridascottonclouds.com/ Meet with Onahira: https://intro.co/ONAHIRARIVAS?source=introFacebook & Instagram: @onahirarivasTikTok: Tiktok@onahirarivasLinkedIn: https://www.linkedin.com/in/onahirarivas

Michele Schneider, Chief Strategist, MarketGauge Group discusses the takeaways for wider markets with the Trump administration taking a 10 percent stake in chipmaker Intel. This comes as White House economic advisor Kevin Hassett says this is part of a broader strategy to create a sovereign wealth fund that could include more companies. She also takes a closer look at Nvidia ahead of its earnings, and why she still like Novo Nordisk despite recent negative headlines. Produced/Presented: Ryan HuangImage by 3D Animation Production Company from PixabaySee omnystudio.com/listener for privacy information.

Ein Fall von Rassismus erschüttert die Polizei von Lausanne. Die Staatsanwaltschaft hat zwei Whatsapp-Gruppen mit diskriminierenden Äusserungen entdeckt. Vier Polizisten wurden bereits suspendiert. (00:00) Intro und Schlagzeilen (01:02) Rassistische Äusserungen: Vier Lausanner Polizisten suspendiert (05:24) Nachrichtenübersicht (09:56) Stabile Zahlen bei der Freiwilligenarbeit in der Schweiz (14:23) Post verschickt keine Pakete mehr in die USA (16:14) Unifil: Der Uno-Mission im Libanon droht das Ende (20:26) Überwachung via Gesichtserkennung wird in England ausgeweitet (25:39) Novo Nordisk in der Krise (30:24) Xenotransplantation: Erstmals Schweinelunge verpflanzt (35:37) Wie hat sich die Berichterstattung zum Umweltschutz verändert?

El director de Divacons-AlphaValue analiza los valores de Iberdrola, Cellnex, Acciona, Novo Nordisk o Nvidia, entre otros.

After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. In this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy break down the numbers behind the industry’s second-quarter performance. Among U.S. pharma heavyweights, J&J, AbbVie, Pfizer, Regeneron, Bristol Myers Squibb and Biogen each eked out gains this past quarter. Their results varied, with individual stories worth highlighting at each of these major companies. Beyond earnings, Sagonowsky and Dunleavy also discuss the growing competition in diabetes and obesity treatments between Eli Lilly and Novo Nordisk, as well as Merck’s rising financial reliance on its blockbuster cancer drug Keytruda, among other topics. To learn more about the topics in this episode: Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year The battle of the obesity drug heavyweights 7 top pharmas posted revenue declines in Q1. The common thread? All are US firms Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview See omnystudio.com/listener for privacy information.

In this episode, our host Maryam Tabatabai is joined by three guests Olivia Pane, PharmD; Dr. Edmundo Rodriguez Frias; and Katie Lockhart, who unpack insights from Prime Therapeutics' latest clinical report that dives into the latest evidence-based clinical insights related to the rising prevalence and significant health impact of metabolic dysfunction-associated steatohepatitis, or MASH. MASH is a silent but serious liver condition affecting over 22 million Americans, with numbers projected to rise sharply by 2030. Listeners learn about the latest major development in liver health treatment: the FDA approval of Novo Nordisk's semaglutide – Wegovy -- as the first GLP-1 drug indicated for MASH. We explore how this development may revolutionize care and could offer a more affordable alternative to treating this condition.The Evolution of GLP-1swww.primetherapeutics.comAll Pharmacy Friends episodesMetabolic dysfunction-associated steatohepatitis (MASH) – A new era in liver healthThe views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice

Regeringen vil i 2026 og 2027 sætte elafgiften ned til næsten 0. Dansk økonomi voksede i andet kvartal. Novo Nordisk indfører ansættelsesstop og varsler flere besparelser. Vanvittig lønkrig om AI-talenter i Silicon Valley. Danish Crown melder om fremgang. Trump langer igen ud mod sol og vind. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)  

US tech stocks sold off on Tuesday, and Federal Reserve chair Jay Powell will be between a rock and a hard place when he delivers his speech at the Jackson Hole Economic Policy Symposium this Friday. Plus, Ozempic-maker Novo Nordisk has fallen behind its rivals. Does it have a plan to catch up? Mentioned in this podcast:Jay Powell to deliver Jackson Hole address under fire on multiple frontsUS tech stocks hit by wave of concerns over future of AI boomHow Novo Nordisk lost its lead in the weight loss raceLabubu frenzy sends Pop Mart profits soaringToday's FT News Briefing was produced by Fiona Symon, Katya Kumkova, Sonja Hutson, and Marc Filippino. Additional help from Kelly Garry, Michael Lello, David da Silva and Gavin Kallmann. Our acting co-head of audio is Topher Forhecz. The show's theme music is by Metaphor Music. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Weight bias is a problem that is often overlooked in our society, which is why advocacy is so crucial. We spoke with Lisa Schaffer, the Executive Director of Obesity Canada, about this important issue...The medical information in this podcast is provided as an information resource only. It is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice and treatment.This episode was sponsored by Novo Nordisk. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.

Muligt møde mellem Rusland, Ukraine og USA og sikkerhedsgarantier. I fremtiden vil AI medføre en voldsom stigning i det globale forbrug af energi. Prisen på Ørsteds fortegningsemission kommer til at vær afgørende. Novo Nordisk tager foreløbig sejr i slagsmål om 6 mia. kr. Midt i en storstilet plan om at satse milliarder på fibernet mister TDC kunder. Tidligere minister kritiserer myndigheders og ministres lukkethed i Panama Papers-sagen.   Vært: Trine Duvander (trine.duvander@borsen.dk)

Het is de dag dat verzekeraar ASR nog met kwartaalcijfers komt. Als een van de laatste Nederlandse beursbedrijven. De cijfers zien goed, maar de populariteit van ASR.... niet echt. Concurrenten als Aegon en NN Group behoren tot de 25 populairste aandelen onder Nederlandse beleggers, maar ASR hoort er niet bij. We zoeken deze aflevering uit waarom ASR in populariteit ver achter ligt op de concurrentie. Ook hoor je of de verzekeringssector nog een goede is om in te beleggen.Beleggen doet de Trump regering ook. Het wil niet alleen een tiende van de aandelen van Intel hebben, het wil nu (volgens persbureau Reuters) óók aandelen opkopen van Samsung en TSMC.En over kopen en Trump gesproken: hij blijkt voor meer dan 100 miljoen dollar aan obligaties gekocht te hebben. Waaronder schuldpapier van Meta. Waarmee hij dus een schuldeiser is van Mark Zuckerberg. Verder hebben we het over de onderhandelingen tussen China en de VS. De gesprekken gaan goed, zegt minister Scott Bessent. Minder goed gaat het bij Palantir. Het aandeel gaat voor de vijfde dag op rij onderuit. In korte tijd is er al 20 procent van het aandeel af.Wat je ook in deze aflevering hoort: Guess what? Guess wordt van de beurs gehaald Beleggers niet blij met de cijfers van Target Pizza Hut aapt de McDonalds na De Spac maakt zijn comeback Elon Musk zet zijn politieke ambities in de ijskast See omnystudio.com/listener for privacy information.

Na een kort zomerreces verzuipt de Trends Beleggen-redactie in de bedrijfsresultaten. Danny Reweghs bespreekt de meest opmerkelijke en relevante van de afgelopen weken met argenx, KBC en Novo Nordisk. In Trends podcasts vind je alle podcasts van Trends en Trends Z, netjes geordend volgens publicatie.  De redactie van Trends brengt u verschillende podcasts over wat onze wereld en maatschappij beheerst.  Vanuit diverse invalshoeken en met een uitgesproken focus op economie en ondernemingen, op business, personal finance en beleggen.  Onafhankelijk, relevant, telkens constructief en toekomstgericht. 

The Indian government has suspended import duties on cotton until the end of September in response to demands from industry groups. The move to exempt them from the 11% levy is seen as a relief for the textile industry, which is facing a steep 50% tariff on shipments to the US. Also, how much would you pay for a cup of coffee? If you're in the US, you could be about to pay a whole lot more due to tariffs. And prices for obesity-treatment drug in the US are expected to drop as Novo Nordisk halves the price of Ozempic.

What if one of biotech's biggest production breakthroughs was hiding in plain sight? Not in a new gene or a wonder drug, but in the way we process and purify biologics.Perfusion technology, once dismissed as a pipedream in top biopharma boardrooms, is now quietly powering some of the industry's most efficient and productive manufacturing platforms. Yet, transforming perfusion from controversial buzzword to gold standard required timing, vision, and a willingness to break from tradition.In this episode, host David Brühlmann sits down with Jarno Robin, a bioprocessing pioneer whose 20+ year journey spans industry giants like Novo Nordisk, Sanofi, and Leo Pharma. Jarno has championed upstream continuous processes, including ATF and TFF, for decades, and now, as a leader at Sani Membranes, he's unleashing the next evolution: Vibro® Membrane Filtration, an innovation set to upend conventional wisdom about fouling, pressure loss, scalability, energy usage, and more.Here are three reasons you'll want to listen to Jarno's journey:Innovation Versus Industry Inertia: Behind every platform shift are years of resistance. Jarno recounts how timing, advocacy, and matching the right data with the right decision-makers finally made perfusion mainstream, even after company leaders proclaimed, “We will never ever run perfusion.”State-of-the-Art and the Next Frontier: ATF and TFF remain dominant, but their limitations, like membrane fouling, scale-up headaches, and high energy needs, are real. Jarno explains how Vibro® Membrane Filtration addresses these pain points with a radically new design, offering lower pressure loss, less fouling, higher cell densities, and surprisingly low energy consumption.Practical Wisdom for Bioprocess Developers: Should you always run a control in process development? How do you translate lab-scale wins to robust, money-earning production? Jarno shares counterintuitive advice based on decades of hands-on success and mistakes.Curious how you can optimize your process technology and sidestep costly pitfalls? Listen to this episode and discover how “timing is everything” in bioprocessing innovation and whether new filtration methods could help you leap ahead.Connect with Jarno Robin:LinkedIn: www.linkedin.com/in/jarno-robinWebsite: www.sanimembranes.comCurious about continuous processing challenges and breakthroughs? Don't miss these previous episodes.Episodes 39-40: Balancing Perfusion Process Development and Sustainability with Jochen SieckEpisodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosNext step:Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über ein Dekadenhoch in China, zwei frohe Botschaften bei Novo Nordisk und Rückenwind bei Windkraftaktien. Außerdem geht es um Rheinmetall, Hensoldt, Renk, Leonardo, Thales, Shanghai Composite, CSI 300, Tencent Music, Nio, Netease, Xiaomi, Tencent, Alibaba, BYD, JD, Vestas, Energiekontor, Siemens Energy, Nordex, SMA Solar, Bayer, GoodRX, Duolingo, Pro7Sat.1, Intel, Nvidia, Home Depot, Starbucks, Netlfix, Sixt, CTS Eventim, Nike, Spotify, Live Nation Entertainment, AMC, Amazon, Kyivstar, VEON. Und hier gibt es die Tickets zum Finance Summit am 17. September! https://veranstaltung.businessinsider.de/FinanceSummit Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Merger Monday mit Übernahmen von: Exklusiv-Club Soho House, Dayforce, Amphenol kauft Kabelhersteller für Rüstungsboom und Berlusconi failed bei Pro7. Den Wind- und Solaranbietern geht's sonnig und Novo Nordisk gewinnt sogar mal gegen Elli Lilly. Hologic (WKN: 879100) setzt sich für die Gesundheit von Frauen ein und das tut nicht nur dem Gewissen, sondern auch dem Geldbeutel gut. Blue OWL (WKN: A2QPLU) produziert Milliardäre mit Privatkrediten an KI-Unternehmen Diesen Podcast vom 19.08.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

We bespreken de beursreactie op Novo Nordisk op groen licht van de Amerikaanse geneesmiddelen-autoriteit. En we bespreken de beursrally in China met analist Patrick Casselman. In Trends podcasts vind je alle podcasts van Trends en Trends Z, netjes geordend volgens publicatie.  De redactie van Trends brengt u verschillende podcasts over wat onze wereld en maatschappij beheerst.  Vanuit diverse invalshoeken en met een uitgesproken focus op economie en ondernemingen, op business, personal finance en beleggen.  Onafhankelijk, relevant, telkens constructief en toekomstgericht. 

Intel’s turnaround story just got bigger—SoftBank is investing $2 billion while the U.S. government may take a 10% stake. Nio is steering its EVs into Singapore for the first time, widening its global footprint. Wall Street holds near record highs as bulls and bears clash ahead of Jerome Powell’s Jackson Hole speech. We play UP or DOWN with Novo Nordisk, Palo Alto Networks, Yangzijiang Financial, and CapitaLand Ascendas REIT. The Straits Times Index slips under 4,200, with ST Engineering, Sembcorp, and Keppel dragging while Frasers Logistics shines. And our Last Word spotlights Judy Faulkner, who built Epic Systems into a health-tech empire from her basement. Hosted by Michelle Martin with Ryan Huang.See omnystudio.com/listener for privacy information.

In this episode, Scott Becker examines GoodRx's 30% surge after entering the weight loss drug market, the rapid growth of hims and hers, and Novo Nordisk's move to cut prices on Ozempic as competition in the GLP-1 space intensifies.

The 5 things you need to know before the stock market opens today: Tesla is reportedly offering discounts to car leasing companies in the UK, Novo Nordisk received FDA approval for a liver disease treatment, Samsung's phone shipments to the U.S. surged in the second quarter, tech company supplier Foxconn will operate a U.S. factory as a joint venture with Softbank, OpenAI, and Oracle, and the Warner Brothers horror film “Weapons” remained number one at the weekend box office.  Squawk Box is hosted by Joe Kernen, Becky Quick and Andrew Ross Sorkin.  Follow Squawk Pod for the best moments, interviews and analysis from our TV show in an audio-first format. 

With the Dow heading into Monday's session in record territory, Carl Quintanilla, David Faber and Mike Santoli explored a big week on tap for the markets -- including Fed Chair Powell's upcoming speech at the Fed symposium in Jackson Hole, Wyoming, as well as retail earnings from Home Depot, Walmart and Target. Novo Nordisk shares get a lift from a double dose of news regarding their blockbuster drugs Wegovy and Ozempic. Also in focus: Ukraine's president and European leaders set to meet with President Trump at the White House, Nvidia rises on analyst calls, why the "force" is with one stock up more than 25% to start the week, Tesla teases a new car in China, a fascinating look at humanoid robots as China showcases advancements in robotics. Squawk on the Street Disclaimer

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored by CNBC's Jessica Ettinger.

This Day in Legal History: Nineteenth Amendment RatifiedOn August 18, 1920, the Nineteenth Amendment to the U.S. Constitution was ratified, guaranteeing women the right to vote and marking a major legal milestone in the struggle for gender equality. The amendment states simply: “The right of citizens of the United States to vote shall not be denied or abridged… on account of sex.” Its passage capped off more than 70 years of organized activism, dating back to the Seneca Falls Convention in 1848. Suffragists like Susan B. Anthony, Elizabeth Cady Stanton, Sojourner Truth, and Alice Paul played pivotal roles in maintaining momentum across generations, despite fierce opposition.The road to ratification was grueling. Congress passed the amendment in 1919, but it still required approval from three-fourths of the states—36 at the time. Tennessee became the critical 36th state, narrowly approving the amendment in a dramatic vote where a 24-year-old legislator, Harry T. Burn, changed his vote after receiving a letter from his mother urging him to support suffrage. That moment tipped the scales and enshrined the right to vote for women nationwide.Before the amendment, several western states had already extended suffrage to women, but many others actively suppressed it. The legal recognition of women's voting rights through constitutional amendment removed any ambiguity and forced all states to comply. The Nineteenth Amendment not only transformed the electorate but also reshaped American democracy by recognizing women as full political participants.The Trump administration is accusing a federal judge in Boston of undermining the authority of the U.S. Supreme Court by continuing to block the administration from firing staff in the Department of Education's Office for Civil Rights. U.S. District Judge Myong Joun had issued an injunction requiring the reinstatement of employees let go in a mass layoff, despite the Supreme Court having recently paused a broader version of that order. The Justice Department has asked the 1st U.S. Circuit Court of Appeals to intervene, arguing that Joun's refusal to lift the narrower injunction contradicts the Supreme Court's ruling and undermines the rule of law.The judge's decision stems from a lawsuit challenging Secretary of Education Linda McMahon's plan to lay off over 1,300 department employees, part of President Trump's broader goal of eliminating the department—something only Congress can authorize. The plaintiffs, including students and advocacy groups, focused specifically on the Office for Civil Rights, which was set to lose half its staff. They argue that lifting the injunction now would effectively reward the administration's ongoing failure to comply with the court's order, as the terminated employees have not yet been reinstated.Judge Joun, appointed by President Biden, criticized the Supreme Court's ruling as "unreasoned" and pointed to the administration's continued noncompliance. The 1st Circuit has asked the plaintiffs to respond promptly to the Justice Department's request, signaling an expedited review.Trump administration claims judge defied Supreme Court to bar Education Department firings | ReutersFederal Reserve Chair Jerome Powell is preparing for what may be his final speech at the annual Jackson Hole conference, facing a complicated economic picture that challenges his data-driven policy approach. In past years, Powell used the conference to pledge aggressive action against inflation and, later, to support the labor market. Now, with inflation still above target and signs of economic slowdown emerging, Powell must decide whether to prioritize price stability or job preservation.The Trump administration and many investors expect interest rate cuts at the Fed's September meeting, but Powell's messaging—how he frames future actions—may matter more than the decision itself. Internally, Fed officials are split: some want to move quickly to protect jobs, while others want to wait for clearer evidence that inflation won't rebound. Powell has previously styled himself after past Fed chairs like Paul Volcker and Alan Greenspan, with Volcker's inflation-fighting resolve and Greenspan's forward-looking leniency both offering competing models.Recent economic data has sent mixed signals. Revised job growth numbers were lower than initially reported, supporting arguments for easing monetary policy, but inflation has edged up again. Trump's tariff policies add further uncertainty, though their economic impact has so far been less severe than feared. With the economy growing slowly and inflation still above the Fed's 2% target, Powell must decide whether to stay the course, cut rates cautiously, or begin a broader shift.Powell has used Jackson Hole to battle inflation and buoy jobs; he's now caught between both | ReutersNovo Nordisk's shares rose by up to 5% after receiving accelerated U.S. approval for its weight-loss drug Wegovy to treat MASH (metabolic dysfunction-associated steatohepatitis), a progressive liver disease that affects about 5% of U.S. adults. This marks the first GLP-1 drug approved for MASH and offers a significant, if temporary, advantage over competitor Eli Lilly, which is still in clinical trials for its own MASH-targeting drug, tirzepatide.The news was a welcome reversal for Novo, which recently lost over $70 billion in market value following a profit warning and leadership change. The company, once Europe's most valuable publicly traded firm due to Wegovy's success, has seen its share price drop sharply over the past year amid intensifying competition in the obesity drug market and the rise of compounded copycat drugs.Although Novo now holds a short-term lead in the liver disease market, analysts expect that exclusivity will be brief once Eli Lilly gains approval. Novo has also submitted applications in Europe and Japan, signaling its intention to secure broader global use for Wegovy beyond weight loss.Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment | ReutersNorton Rose's ambitious tech partnership with NMBL Technologies has ended in failure and mutual lawsuits, highlighting how difficult it is for Big Law firms to pivot from selling legal services to selling tech products. The firm's Chicago office, launched in 2022 as an “innovation hub,” aimed to introduce 150 clients to Proxy, a legal workflow tool developed by a new partner, Daniel Farris. But three years later, not a single sale was made. NMBL claims Norton Rose didn't uphold its end of the deal and stifled the rollout, while the firm says clients weren't interested and is seeking damages for the investment.The fallout underscores broader challenges law firms face as they increasingly invest in artificial intelligence and legal tech amid growing demand and rising budgets. Unlike traditional legal work, selling products requires different infrastructure and skills—such as dedicated sales teams—that most law firms lack. Despite producing marketing materials and training resources, NMBL alleges that very few Norton Rose lawyers engaged with the product and that the firm failed to meaningfully promote it.NMBL is seeking $15 million in damages, accusing the firm of using the deal merely to recruit talent, while Norton Rose wants $250,000, calling the product commercially nonviable. The firm also allegedly created a shell subsidiary, LX, to meet contract terms but never properly funded or activated it. This case illustrates the steep learning curve law firms face in transitioning to tech-based business models and the internal resistance that can derail innovation.Firm's Failed Tech Venture Foretells Big Law's AI Sales Struggle This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Stock Market update for August 18, 2025. This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

In this episode, Scott Becker examines GoodRx's 30% surge after entering the weight loss drug market, the rapid growth of hims and hers, and Novo Nordisk's move to cut prices on Ozempic as competition in the GLP-1 space intensifies.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über Börsen-Non-Event Alaska, eine hoffnungsvolle Softwarestudie mit 6 Top Picks und einen neuen Chart of Doom. Außerdem geht es um CoreWeave, Salesforce, Siemens Energy, Cisco Systems, Palo Alto Networks, ProSiebenSat.1, Novo Nordisk, AstraZeneca, AbbVie, Siemens Healthineers, Sonova, Medtronic, Haleon, iShares Aging Population ETF (WKN: A2ANH1), Boston Scientific, Glaukos, Exelixis, Sarepta, Swisscanto Healthy Longevity Fund (WKN: A40L0T), Eli Lilly, Abbott, UnitedHealth, Microsoft, Amazon, Nvidia, Meta, Netflix, Coreweave, Oracle, Carvana, TSMC, Roblox, Crowdstrike, Opendoor Technologies, Alibaba, PDD, Petroleo Brasileiro, Teva Pharmaceutical, Robinhood, Northrop Grumman, RTX, Lululemon, Mercadolibre, Talen Energy, GE Vernova, Broadcom, Vistra, Micron, Alphabet, Somnigroup International, Flutter Entertainment. Und hier gibt es die Tickets zum Finance Summit am 17. September! https://veranstaltung.businessinsider.de/FinanceSummit Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Je hoeft nooit te wachten tot je Bitcoins mag kopen. Dat kan 24 uur per dag, 365 dagen per jaar. Maar voor Amsterdam Bitcoin Treasury Strategy mag je gewoon wachten totdat het Damrak open gaat. Toch is AMBTS niets meer dan een pot Bitcoins, in het leven geroepen door cryptoplatform Amdax. De ambitie is om 1 procent van alle Bitcoins op te kopen en ze vervolgens op de Amsterdamse beurs te laten verhandelen door pensioenfondsen en andere institutionele beleggers die formeel geen toestemming hebben om hun geld in cryptovaluta te steken. Puik idee? Laat idee? Zoveelste voorbeeld van cryptopotten, waarvan er al honderden bestaan op aarde? Of toch een voorbeeld van de democratisering van de cryptomarkten? U mag het zeggen. Verder praten we over Apple, dat marktaandeel verliest aan Samsung in de VS. De vouwbare telefoons zijn hot en de iPhone verliest terrein. Moet Apple ook in de vouwtelefoons stappen? En waar blijft die AI-strategie eigenlijk? Robbert Manders van Antaurus Europe Fund buigt zich over de strategie van de reus uit Cupertino. Ook bespreken we het voorzichtige herstel van zowel Adyen als Novo Nordisk. Beide brekebeentjes hebben de wind in de rug. Adyen krijgt misschien lagere koersdoelen, maar de koopadviezen van analisten blijven staan. En Novo Nordisk ziet het zoveelste multifunctionele medicijn: afslankprik Wegovy is goedgekeurd voor een heftige leveraandoening. Tot slot valt ook het woord 'AI' weer in de uitzending. Dat ligt niet aan ons. Sam Altman van OpenAI zegt namelijk dat zijn sector zich in een bubbel bevindt. Of ChatGPT dat met hem eens is, laat zich raden. See omnystudio.com/listener for privacy information.

I fredags mødtes Putin og Trump, i dag mødes Trump, Zelenskyj og europæiske ledere. 300.000 på gaden i Tel Aviv. Novo Nordisk godkendes til behand­ling af fedtlever i USA. Usædvanlig handel­sak­ti­vitet i Bavarian, før købsrygte ramte markedet, skaber insiderrygter. Lakrids by Bülow solgt til kapital­fond fra Kina. Sådan har Trump gjort værdier til handels­bar­ri­erer.   Vært: Trine Duvander (trine.duvander@borsen.dk)

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s GLP-1s quarter after quarter, this most recent earnings season delivered a few surprises. It’s a good moment to jump back in and assess where the two rivals stand in the market and where their pipelines are headed in the near term. In this week’s episode of "The Top Line," we break down the recent commercial performances of Novo’s and Lilly’s drugs for diabetes and obesity, plus the status of their oral obesity med prospects. Fierce Biotech’s James Waldron sits down with Fierce Pharma’s Fraiser Kansteiner to discuss the latest in the companies’ ongoing obesity duel, as well as some recent pitfalls that seem common to GLP-1 development and commercialization more broadly. To learn more about the topics in this episode: Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist Amid MFN talks, Lilly chief warns US adoption of international drug prices could bring 'worst of two worlds' Novo Nordisk drops 2 obesity drugs as part of major pipeline clearout Lilly's oral GLP-1 data 'as good as it gets' at 12% weight loss, exec says Pfizer's embattled obesity program loses another GLP-1 over poor data and strong competition See omnystudio.com/listener for privacy information.

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week on Market Mondays, we dive deep into the biggest stories shaking markets, tech, and culture. From Nvidia and AMD's controversial China concessions to OpenAI's latest model fueling AI valuation fever, we unpack what's hype and what's real. Tesla gets the green light for robotaxi testing in Texas, Samsung might make a surprise search engine move before Apple, and the Nasdaq's record-breaking run sparks debate: is it a healthy bull leg or the start of a dangerous climb? We also explore S&P bear market risks, Visa's battle with stablecoins, the weight-loss drug shakeout, and oil's potential drop into the $60s.We're also watching game-changing shifts in consumer behavior and corporate strategy. AI agents shopping on your behalf, the dominance (and risks) of mega-cap tech, and the single number that could change your investment plan this week. Plus, Las Vegas hotel occupancy dips, the AI server boom-or-bust debate, health giants like UnitedHealth and Novo Nordisk facing turbulence, and the seasonal swing trades that could set you up before “Uptober.” We break down high-conviction trade plans, ASML's puzzling stock action, and a potential sports + streaming mash-up with Disney, ESPN, and the NFL.It's a conversation about power, ownership, and what happens when athletes take control of their brand like never before. Whether it's chips, crypto, commodities, or culture, we've got the insight you need to make smarter moves in today's market.#MarketMondays #EarnYourLeisure #StockMarket #Investing #Nvidia #AMD #AI #Tesla #Nasdaq #S&P500 #Visa #Stablecoins #WeightLossDrugs #OilPrices #AIShopping #BigTech #LasVegas #AIservers #HealthcareStocks #SwingTrading #ASML #SportsBusiness #ShedeurSandersOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

[Join our community at my Substack where we continue these conversations with deeper dives into the biggest lessons from each episode, plus my regular essays and behind-the-scenes thoughts: https://bogumilbaranowski.substack.com/] James Emanuel is a London-based contrarian investor and founder of Rock and Turner who discovers fundamentally misunderstood companies trading at massive discounts while building his reputation through popular Substack newsletter research and his book "Fabric of Success."3:00 - Emanuel's intellectual curiosity shaped his contrarian approach: "I take nothing at face value. I question absolutely everything" - discusses how questioning religious beliefs as a child developed critical thinking essential for investing6:00 - The Rolex story reveals value perception: bought same expensive watch as colleague but paid significantly less, demonstrating "price is what you pay, but value is what you get" - watch now worth 3x original price9:00 - Law background creates analytical advantage: legal training teaches structured thinking and considering counterarguments, invaluable for examining investment downside risks12:00 - Convergence theory and "golden threads": successful businesses across different eras/industries evolve similar approaches - like sharks and dolphins reaching similar design through different evolutionary paths15:00 - People matter most: "The jockey is more important than the horse" - Apple's near-bankruptcy under Scully vs. massive success under Jobs proves same company with different leader becomes entirely different investment18:00 - Succession planning as golden thread: best companies promote from within (Novo Nordisk had only 5 CEOs in 103 years, Costco leaders worked up from entry-level)21:00 - Bureaucracy as "corporate virus": processes become more important than results, stifling innovation and driving away top talent24:00 - Stock screeners are garbage: statutory accounts weren't designed for investors, focus on qualitative analysis over quantitative metrics27:00 - John Malone created EBITDA metric because Wall Street couldn't understand his tax-minimizing strategy - TCI became 900-bagger despite appearing expensive on earnings multiplesPodcast Program – Disclosure StatementBlue Infinitas Capital, LLC is a registered investment adviser and the opinions expressed by the Firm's employees and podcast guests on this show are their own and do not reflect the opinions of Blue Infinitas Capital, LLC. All statements and opinions expressed are based upon information considered reliable although it should not be relied upon as such. Any statements or opinions are subject to change without notice.Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed.Information expressed does not take into account your specific situation or objectives, and is not intended as recommendations appropriate for any individual. Listeners are encouraged to seek advice from a qualified tax, legal, or investment adviser to determine whether any information presented may be suitable for their specific situation. Past performance is not indicative of future performance.

Kara and Scott discuss the advancement of a bill to ban stock trading by lawmakers, President Trump's Joe Rogan problem, and Ghislaine Maxwell agreeing to testify for immunity. Then, President Trump says he will not extend the latest August 1st tariff deadline, and Microsoft and Meta's mega earnings. Plus, Novo Nordisk shares are plummeting after weak growth for Ozempic and Wegovy. Watch this episode on the ⁠⁠Pivot YouTube channel⁠⁠.  Follow us on Instagram and Threads at ⁠⁠@pivotpodcastofficial⁠⁠.  Follow us on Bluesky at ⁠⁠@pivotpod.bsky.social⁠⁠.  Follow us on TikTok at ⁠⁠@pivotpodcast⁠⁠.  Send us your questions by calling us at 855-51-PIVOT, or at ⁠⁠nymag.com/pivot⁠⁠.⁠⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Uggs' sales are surging thanks to men… And it's not the only brand pulling off a gender pivot.Novo Nordisk stock is down 65%... because “inventing” something doesn't mean “winning” it.The Federal Reserve made its interest rate decision… no change. We explain the Debbie Downer decision.Reese's & Oreos just teamed up despite being rivals… Enemies with benefits$HSY $MDLZ $DECK $NVO $SPYWant more business storytelling from us? Check out the latest episode of our new weekly deepdive show: The untold origin story of… The Skateboard